Biochem/physiol Actions

CP-101,606 is an NR2B (N-methyl D-aspartate receptor subtype 2B) subunit antagonist, that can increase dyskinesia. It reduces Ca²⁺/calmodulin-dependent protein kinase II level, at threonine-286 hyperphosphorylation (pCaMKII-Thr286). It has no effect on the α1-adrenergic receptors. CP-101,606 has the ability to inhibits the habits, stimulated by cocaine. It also possesses hallucinogenic properties.

CP-101606 mesylate (Traxoprodil mesylate) is a potent noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors, selective for the NR2B subunit. CP-101606 mesylate has been shown to be neuroprotective in animal models of brain injury and stroke.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Neuroscience research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle